Q32 Bio (NASDAQ:QTTB) Research Coverage Started at SVB Leerink

Equities researchers at SVB Leerink began coverage on shares of Q32 Bio (NASDAQ:QTTB) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $54.00 price target on the stock. SVB Leerink’s target price points to a potential upside of 81.45% from the stock’s current price.

Other analysts have also issued research reports about the company. Piper Sandler assumed coverage on Q32 Bio in a report on Tuesday, April 2nd. They set an “overweight” rating and a $45.00 target price on the stock. Oppenheimer initiated coverage on Q32 Bio in a research report on Thursday, April 11th. They set an “outperform” rating and a $50.00 price target on the stock.

Q32 Bio Stock Down 1.1 %

Shares of Q32 Bio stock opened at $29.76 on Tuesday. The company has a quick ratio of 4.19, a current ratio of 4.19 and a debt-to-equity ratio of 0.19. Q32 Bio has a 12 month low of $8.24 and a 12 month high of $32.88. The firm has a market cap of $97.02 million, a P/E ratio of -0.91 and a beta of -0.26.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($4.32) EPS for the quarter. As a group, equities research analysts expect that Q32 Bio will post -10.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Q32 Bio

Several institutional investors and hedge funds have recently made changes to their positions in QTTB. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Q32 Bio in the first quarter valued at approximately $35,649,000. Carlyle Group Inc. acquired a new stake in shares of Q32 Bio during the 1st quarter worth $18,074,000. Vivo Capital LLC acquired a new stake in shares of Q32 Bio during the 1st quarter worth $6,306,000. ARCH Venture Management LLC bought a new position in shares of Q32 Bio in the first quarter worth $5,461,000. Finally, Platinum Investment Management Ltd. acquired a new position in Q32 Bio in the first quarter valued at about $1,874,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy.